Relationship between calculated 90% CI and sign. treatment effect in BE [General Sta­tis­tics]

posted by GM – India, 2017-03-29 14:11 (2575 d 04:38 ago) – Posting: # 17202
Views: 8,676

Hi David,

❝ The problem might be on the estimate statement. If the 90% CI is significantly different from 1, then the p-value for "formulation" should also be significant at the 10% significance level. Maybe you're using a different denominator than expected...


❝ It would be easier if you post the full glm code.


Here is the code used for my analysis.

Proc GLM data=logdata;
   class Sequence Subject Period Form Cohort;
   model Log(Param) = Sequence Period Form Cohort Form*Cohort Subject(Sequence*Cohort)/ SS3;
   output out=outlier rstudent=student;
   test h=Sequence e=Subject(Sequence*Cohort) / htype=3 etype=3;
   lsmeans Form / pdiff CL alpha=0.10;
   estimate 'A VS B' Form 1 -1;
run;


I got the values for CI is 77.27-98.78 (doesn't contain 100%) and p-value of treatment effect is 0.0709 (not significant at the 5% level).

My observation is that when removing the Form*Cohort term from the model, treatment effect is significant @5% level of significance.

My question is that the terms which are used in the model are sufficient or not...? and if it is correct, why p-value of treatment effect is not significant...?:confused:

Thanks,
GM.

Best Regards,
GM

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,651 registered users;
43 visitors (0 registered, 43 guests [including 8 identified bots]).
Forum time: 18:50 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5